Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

Date Title Document
July 07, 2014 ENDO AND BIODELIVERY SCIENCES ANNOUNCE POSITIVE TOP-LINE RESULTS FROM THE PHASE III CLINICAL TRIAL OF BEMA BUPRENORPHINE
June 26, 2014 BioDelivery Sciences Announces Completion of Patient Enrollment in its Initial Phase 3 Trial of Clonidine Topical Gel for Painful Diabetic Neuropathy
June 11, 2014 BioDelivery Sciences Featured on Bloomberg TV, TheStreet.com and Business News Network
June 10, 2014 BioDelivery Sciences to Present at the William Blair and Wells Fargo Healthcare Conferences
June 09, 2014 BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence
June 06, 2014 BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence
May 08, 2014 BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials
May 08, 2014 BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
May 06, 2014 BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
April 07, 2014 BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon